Benjamin F. Edwards & Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$17K	Buy	1,012 +281	+38%	+$4.54K	﹤0.01%	1582
2024 Q1	$14K	Buy	731 +131	+22%	+$3.25K	﹤0.01%	1613
2023 Q4	$19K	Hold	600	–	–	﹤0.01%	1493
2023 Q3	$13K	Hold	600	–	–	﹤0.01%	1330
2023 Q2	$14K	Hold	600	–	–	﹤0.01%	1345
2023 Q1	$11K	Hold	600	–	–	﹤0.01%	1377
2022 Q4	$10K	Hold	600	–	–	﹤0.01%	1416
2022 Q3	$10K	Hold	600	–	–	﹤0.01%	1380
2022 Q2	$8K	Hold	600	–	–	﹤0.01%	1414
2022 Q1	$15K	Buy	600 +300	+100%	+$7.26K	﹤0.01%	1277
2021 Q4	$7K	Hold	300	–	–	﹤0.01%	1446
2021 Q3	$5K	Hold	300	–	–	﹤0.01%	1507
2021 Q2	$7K	Hold	300	–	–	﹤0.01%	1440
2021 Q1	$8K	Buy	300 +100	+50%	+$4.4K	﹤0.01%	1400
2020 Q4	$11K	Buy	+200	New	+$9.93K	﹤0.01%	1260

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Benjamin F. Edwards & Company's ACAD Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Acadia Pharmaceuticals (ACAD) stake by 38% in Q2 2024, buying an estimated $4.54K and bringing the position to 1,012 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

Benjamin F. Edwards & Company first reported a position in ACAD in Q4 2020 and has held it in 15 quarters since. The position peaked at $19K in Q4 2023. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

Benjamin F. Edwards & Company held 1,012 shares of Acadia Pharmaceuticals worth $17K as of Q2 2024.
Benjamin F. Edwards & Company bought 281 Acadia Pharmaceuticals shares in Q2 2024, an estimated $4.54K.
Acadia Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1582 holding.
Benjamin F. Edwards & Company first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
Benjamin F. Edwards & Company's Acadia Pharmaceuticals position peaked at $19K in Q4 2023.
264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.